Ways to improve the quality of life of patients with metabolically associated fatty liver disease

Recently, the incidence of metabolically associated fatty liver disease (MAFLD) has been increasing rapidly worldwide. The formation of MAFLD is associated with obesity, metabolic disorders, as well as an increased risk of cardiovascular diseases and mortality. In recent years, more and more attention has been paid to the quality of life of patients with MAFLD. The purpose of the review article is to study a comprehensive assessment of the quality of life of patients with MAFLD and the development of culturally sensitive measures and strategies aimed at eliminating structural barriers to improving the health of people with metabolic syndrome, assessing the impact of lifestyle modification, nutrition, and various drug therapy strategies for patients on quality of life. Materials and methods. The analysis of recent publications on the PubMed site devoted to the study of quality of life indicators for patients with MAFLD and strategies to improve them has been carried out. Based on the analysis of recent publications, it was noted that body mass index, triglyceride levels, ALT, severity of MAFLD, diabetes mellitus, depression and cardiovascular diseases were factors influencing the decrease in CLDQ indicators, which proved the influence of socio-demographic and clinical factors associated with MAFLD on a decrease in patients’ quality of life. Patients with MAFLD are getting worse, especially in the physical sphere. At the same time, weakness and a decrease in sexual function play a great role in this. It has been convincingly shown that dietary modification, increased physical activity, the use of telemedicine monitoring of patients’ adherence to prescribed recommendations, as well as therapy using Resmetirom, Semaglutide and Terzepatide increase the quality of life of patients. Taking into account the positive effects of essential phospholipids according to the results of the 4th phase of the EXCEL study on improving the quality of life of patients with MAFLD, these drugs can replenish the growing arsenal of complex treatment of patients with MAFLD.